Identification of Inflammatory Mediators Associated with Metastasis of Oral Squamous Cell Carcinoma in Experimental and Clinical Studies: Systematic Review

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2019 Sep 28

PMID 31559586

Citations 9

Authors

Moustafa Elhousiny

Kate Miller

Anura Ariyawadana

Alan Nimmo

Affiliations

Soon will be listed here.

Abstract

Metastasis, whether regional or distant, remains the main cause of morbidity and recurrence in oral cancer. The accumulating evidence suggests that inflammatory mediators are strong drivers for cancer progression and spread. However, the precise role of these inflammatory mediators in mediating specific metastatic stage is poorly understood due to lack of integration/validation of experimental research data and the clinical trials, i.e., the data produced from research is not translated to clinical therapeutic targets. This, in turn, results in the lack of developing reliable biomarker that can be used for accurate diagnosis/prognosis of the tumour spread. We have performed a systematic review to assess the role of inflammatory mediators as potential markers for diagnosis/prognosis of oral squamous cell carcinoma (OSCC) metastasis. We carried out a systematic search the PubMed, Web of Science, Embase and Scopus databases under the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Australian National Health and Medical Research Council (NHMRC). Articles were divided into two groups; experimental (in-vivo) and clinical studies. The REporting recommendations for tumour MARKer prognostic studies Scale (REMARK) was used to assess the quality of the studies for the clinical search while Animal research: Reporting In-vivo experiments (ARRIVE) guidelines were used to assess the quality of the animal studies. Sixteen articles in the clinical group and four articles in the experimental group were included in the final review. We identified nine inflammatory mediators; CXCR4, CXCL12 (SDF-1), CCR7, IL-6, IL-18, CCL20 (MIP-3), CXCL1 (GRO-1), CCL3, CXCR2. This panel of inflammatory mediators can provide a framework for hypothesis testing of the potential value of these mediators in metastatic prognosis. We recommend carrying a large cohort study with data pooling for adequate assessment and testing of the inflammatory panel of mediators.

Citing Articles

PRF Lysates Modulate Chemokine Expression in Oral Squamous Carcinoma and Healthy Epithelial Cells.

Afradi Z, Panahipour L, Abbas Zadeh S, Gruber R Bioengineering (Basel). 2024; 11(8).

PMID: 39199704 PMC: 11351820. DOI: 10.3390/bioengineering11080746.

Plasma IL-1 and IL-6 Family Cytokines with Soluble Receptor Levels at Diagnosis in Head and Neck Squamous Cell Carcinoma: High Levels Predict Decreased Five-Year Disease-Specific and Overall Survival.

Aarstad H, Moe S, Lybak S, Bruserud O, Anderson Tvedt T, Aarstad H Cancers (Basel). 2024; 16(8).

PMID: 38672565 PMC: 11048558. DOI: 10.3390/cancers16081484.

Salivary Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor of Oral Premalignant and Malignant Disorders: A Prospective Study.

Magdum D, Kulkarni N, Kavle P, Paraye S, Pohankar P, Giram A Cureus. 2024; 16(3):e56273.

PMID: 38623101 PMC: 11017949. DOI: 10.7759/cureus.56273.

IRF4 as a novel target involved in malignant transformation of oral submucous fibrosis into oral squamous cell carcinoma.

Meng L, Jiang Y, You J, Zhao P, Liu W, Zhao N Sci Rep. 2023; 13(1):2775.

PMID: 36797470 PMC: 9935854. DOI: 10.1038/s41598-023-29936-8.

Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors.

Geisler L, Hellberg T, Lambrecht J, Jann H, Knorr J, Eschrich J J Clin Med. 2022; 11(20).

PMID: 36294509 PMC: 9604855. DOI: 10.3390/jcm11206191.

References

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

Shah I, Sefvan O, Luqman U, Ibrahim W, Mehmood S, Alamgir W . Clinical stage of oral cancer patients at the time of initial diagnosis. J Ayub Med Coll Abbottabad. 2012; 22(3):61-3. View

Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2008; 45(4-5):309-16. DOI: 10.1016/j.oraloncology.2008.06.002. View

Amit M, Yen T, Liao C, Binenbaum Y, Chaturvedi P, Agarwal J . Clinical nodal stage is a significant predictor of outcome in patients with oral cavity squamous cell carcinoma and pathologically negative neck metastases: results of the international consortium for outcome research. Ann Surg Oncol. 2013; 20(11):3575-81. DOI: 10.1245/s10434-013-3044-0. View

Nanba K, Seki R, Iwata K . [Optic disc measurements in normal subjects by computerized image analysis]. Nippon Ganka Gakkai Zasshi. 1988; 92(11):1889-95. View

Abu El-Naaj I, Leiser Y, Shveis M, Sabo E, Peled M . Incidence of oral cancer occult metastasis and survival of T1-T2N0 oral cancer patients. J Oral Maxillofac Surg. 2011; 69(10):2674-9. DOI: 10.1016/j.joms.2011.02.012. View

Pignon J, Le Maitre A, Maillard E, Bourhis J . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1):4-14. DOI: 10.1016/j.radonc.2009.04.014. View

Chiang A, Massague J . Molecular basis of metastasis. N Engl J Med. 2008; 359(26):2814-23. PMC: 4189180. DOI: 10.1056/NEJMra0805239. View

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

10.

Brooks S, Lomax-Browne H, Carter T, Kinch C, Hall D . Molecular interactions in cancer cell metastasis. Acta Histochem. 2009; 112(1):3-25. DOI: 10.1016/j.acthis.2008.11.022. View

11.

Bergers G, Benjamin L . Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3(6):401-10. DOI: 10.1038/nrc1093. View

12.

Nguyen D, Bos P, Massague J . Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9(4):274-84. DOI: 10.1038/nrc2622. View

13.

Madsen C, Sahai E . Cancer dissemination--lessons from leukocytes. Dev Cell. 2010; 19(1):13-26. DOI: 10.1016/j.devcel.2010.06.013. View

14.

Wu Y, Zhou B . Inflammation: a driving force speeds cancer metastasis. Cell Cycle. 2009; 8(20):3267-73. PMC: 3702728. DOI: 10.4161/cc.8.20.9699. View

15.

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

16.

Hussain S, Harris C . Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007; 121(11):2373-80. DOI: 10.1002/ijc.23173. View

17.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005; 23(36):9067-72. DOI: 10.1200/JCO.2004.01.0454. View

18.

Kilkenny C, Browne W, Cuthill I, Emerson M, Altman D . Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1577-9. PMC: 2936830. DOI: 10.1111/j.1476-5381.2010.00872.x. View

19.

Ishikawa T, Nakashiro K, Hara S, Klosek S, Li C, Shintani S . CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. Int J Oncol. 2005; 28(1):61-6. View

20.

Uchida D, Begum N, Almofti A, Nakashiro K, Kawamata H, Tateishi Y . Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. Exp Cell Res. 2003; 290(2):289-302. DOI: 10.1016/s0014-4827(03)00344-6. View